Bone and Soft Tissue (including Sarcoma) Clinical Trials in Georgia

Cancer Type = Bone and Soft Tissue (including Sarcoma)

Cancer Type = Bone and Soft Tissue (including Sarcoma)

There are currently 24 active Bone and Soft Tissue (including Sarcoma) clinical trials in Georgia.
1.
A Multicenter, Open-Label Study of CMX001 Treatment of Serious Diseases or Conditions Caused By dsDNA Viruses
Cancer Type
Bone and Soft Tissue (including Sarcoma)
NCI ID
NCT01143181
Protocol IDs
CMX001-350
1986
2.
A Non-randomized, Open-label, Multi-center, Phase I / II Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Copanlisib in Pediatric Patients With Relapsed / Refractory Solid Tumors or Lymphoma
Cancer Type
Bone and Soft Tissue (including Sarcoma), Ewing Sarcoma, Lymphoma, Neuroblastoma
NCI ID
NCT03458728
Protocol IDs
19176
NCI-2018-00809
2017-000383-15
3.
A Phase 1 / 2 Study of VX15 / 2503 in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors
Cancer Type
Bone and Soft Tissue (including Sarcoma)
NCI ID
NCT03320330
Protocol IDs
ADVL1614
ADVL1614
NCI-2017-01103
4.
A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Cancer Type
Bone and Soft Tissue (including Sarcoma), Chondrosarcoma
NCI ID
NCT02601937
Protocol IDs
EZH-102
NCI-2015-02224
6.
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma
Cancer Type
Bone and Soft Tissue (including Sarcoma)
NCI ID
NCT03141684
Protocol IDs
10005
NCI-2016-01040
17-C-007
CC 17-C-0074
17-C-0074
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
9.
A Phase I Study of Mesenchymal Stromal Cells for the Treatment of Acute and Chronic Graft versus Host Disease
Cancer Type
Bone and Soft Tissue (including Sarcoma)
NCI ID
NCT02359929
Protocol IDs
EPIC2014-MSC002
NCI-2015-00170
EPIC-MSC002
10.
A Phase I Study of Neihulizumab (AbGn-168H) in Patients With Steroid-refractory Acute Graft-versus-host Disease (Sr-aGvHD)
Cancer Type
Bone and Soft Tissue (including Sarcoma)
NCI ID
NCT03327857
Protocol IDs
2017.002.01
NCI-2018-01343
11.
NCORP Trial
A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM)
Cancer Type
Bone and Soft Tissue (including Sarcoma), Melanoma
NCI ID
NCT02775851
Protocol IDs
S1512
NCI-2016-00666
13.
NCORP Trial
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Cancer Type
Appendix Cancer, Bone and Soft Tissue (including Sarcoma), Brain Cancer , Colon/Rectal Cancer, Unknown Primary
NCI ID
NCT02834013
Protocol IDs
S1609
NCI-2016-01041
Treatment Sites (1)
14.
Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma
Cancer Type
Bone and Soft Tissue (including Sarcoma)
NCI ID
NCT03206450
Protocol IDs
ALTE16C1
ALTE16C1
COG-ALTE16C1
NCI-2017-01152
15.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations
Cancer Type
Bone and Soft Tissue (including Sarcoma), Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Unknown Primary
NCI ID
NCT03698994
Protocol IDs
APEC1621J
APEC1621J
NCI-2018-02150
16.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Tumors Harboring FGFR1 / 2 / 3 / 4 Alterations
Cancer Type
Bone and Soft Tissue (including Sarcoma), Brain Cancer , Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Rhabdomyosarcoma, Unknown Primary
NCI ID
NCT03210714
Protocol IDs
APEC1621B
APEC1621B
NCI-2017-01159
17.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions
Cancer Type
Bone and Soft Tissue (including Sarcoma), Brain Cancer , Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Rhabdomyosarcoma, Unknown Primary
NCI ID
NCT03213704
Protocol IDs
APEC1621A
APEC1621A
NCI-2017-01264
APEC1621A
18.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes
Cancer Type
Bone and Soft Tissue (including Sarcoma), Brain Cancer , Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Unknown Primary
NCI ID
NCT03526250
Protocol IDs
APEC1621I
APEC1621I
NCI-2018-00863
19.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes
Cancer Type
Bone and Soft Tissue (including Sarcoma), Brain Cancer , Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Rhabdomyosarcoma, Unknown Primary
NCI ID
NCT03233204
Protocol IDs
APEC1621H
APEC1621H
NCI-2017-00766
APEC1621H
20.
NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of Ly3023414 in Patients with Solid Tumors
Cancer Type
Bone and Soft Tissue (including Sarcoma), Brain Cancer , Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Unknown Primary
NCI ID
NCT03213678
Protocol IDs
APEC1621D
APEC1621D
NCI-2017-01249
APEC1621D
21.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Braf V600 Mutations
Cancer Type
Bone and Soft Tissue (including Sarcoma)
NCI ID
NCT03220035
Protocol IDs
APEC1621G
APEC1621G
NCI-2017-01244
APEC1621G
22.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Cancer Type
Bone and Soft Tissue (including Sarcoma), Brain Cancer , Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Rhabdomyosarcoma, Unknown Primary
NCI ID
NCT03155620
Protocol IDs
APEC1621SC
APEC1621SC
NCI-2017-01251
APEC1621SC
23.
Phase II Study of Nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent / Refractory Sarcoma in Teenagers and Young Adults
Cancer Type
Bone and Soft Tissue (including Sarcoma), Ewing Sarcoma
NCI ID
NCT02945800
Protocol IDs
MCC-18613
NCI-2016-01837
Georgia CORE

 

Hearts and Minds Dedicated to Improving Cancer Care

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.